Skip to main content
DF

Drug Fix

3episodes
1podcast

Featured On 1 Podcast

All Appearances

3 episodes

AI Summary

→ WHAT IT COVERS Two former senior FDA executives from Canal Row Advisors — Doug Stern and Michael Rogers — analyze the deteriorating state of FDA facility inspections, covering staffing attrition, the generalist inspector shift, foreign inspection logistics, OAI classification consequences, and the agency's likely pivot toward third-party and signal-based oversight models. → KEY INSIGHTS - **OAI Classification Risk:** Firms classified as Official Action Indicated face compounding jeopardy as reinspection capacity shrinks. One client cited OAI classifications dating to 2018 and 2022 still unresolved, resulting in 15–20% lost market share because business partners refused engagement. Firms should treat OAI avoidance as a core business continuity strategy, not merely a compliance checkbox. - **User Fee Fiscal Hygiene:** Each GDUFA-funded investigator has roughly 950 productive annual hours legally designated for generic drug oversight. Deploying those investigators on food, device, or biologics inspections creates legal and fiscal misalignment across user fee programs. Firms should ask FDA directly how it will demonstrate that appropriated and user-fee dollars are being spent as congressionally intended. - **Foreign Inspection Structural Limits:** Unannounced foreign inspections require two investigators per site for safety, consume full weeks with no extension flexibility, and depend on support staff now reduced by the 2025 reorganization. The administration's stated goal of increasing unannounced foreign inspections cannot be achieved at current resource levels — firms with foreign manufacturing sites should prepare for longer reinspection timelines. - **Training Infrastructure Collapse:** The Office of Training and Educational Development faced cuts before 2025, and center-based training units that were meant to replace it have since been reduced or eliminated. With a concurrent hiring freeze, new investigators cannot be trained to replace departing senior national experts. Firms should assume incoming inspectors may have less program-specific expertise and prepare documentation systems legible to generalist reviewers. - **Alternative Oversight Tools Emerging:** FDA is moving toward leveraging third-party audit data, foreign government recall decisions under Section 804(a)(2) to block imports without independent FDA evaluation, and environmental signals like regional floods or sudden excipient price drops as inspection triggers. Firms should consider voluntarily sharing third-party audit results and monitoring foreign regulatory actions affecting their supply chains proactively. → NOTABLE MOMENT Rogers revealed that the 2025 reduction in force deliberately avoided targeting field investigators, yet still damaged inspection capacity significantly — because the eliminated support staff who planned foreign trips, processed travel vouchers, and issued assignments were the operational engine that made inspections possible at all. 💼 SPONSORS None detected 🏷️ FDA Inspections, OAI Classification, Foreign Drug Manufacturing, Pharmaceutical Compliance, FDA Staffing Crisis

AI Summary

→ WHAT IT COVERS Recorded February 27, 2026, Drug Fix covers the Association for Accessible Medicines annual conference with Dave Wallace and Matt Hobbs reporting on generics industry momentum, biosimilar regulatory streamlining, US manufacturing reshoring pressures, and FDA Commissioner Martin McCarry's controversial compassionate use comments raising political interference concerns. → KEY INSIGHTS - **Generics industry positioning:** The generics sector has shifted from defensive advocacy to offensive lobbying by aligning its cost-reduction message directly with the Trump administration's efficiency priorities. AAM CEO John Murphy's strategy includes targeting lawmakers with state-level employment arguments or policy-alignment pitches depending on political affiliation, producing measurable wins including tariff exemptions and PBM legislation. - **Biosimilar development economics:** FDA's October guidance eliminating the default requirement for clinical endpoint studies opens previously unviable biologic targets to biosimilar competition. The prior requirement for Phase III trials made many lower-volume biologics economically unfeasible. Developers should now audit their pipelines against the "biosimilar void" — biologics already off-patent with zero competition in development — identified in AAM's IQVIA study. - **Biosimilar market consolidation:** Expect near-term consolidation among biosimilar developers, per Biocon's Matt Eric at the AAM conference. Markets around adalimumab and ustekinumab already support nine to ten competing developers, which is unsustainable. Fewer developers per molecule may actually improve market viability, though high-value pipeline targets like upcoming blockbuster biologics will continue attracting overcrowded competition. - **US manufacturing reshoring:** Generics and small-cap biosimilar firms cannot match big pharma's multi-billion-dollar US manufacturing pledges, creating a competitive disadvantage in tariff negotiations. The sector's practical strategy involves identifying which APIs and finished dosage forms are feasible to produce domestically and pursuing government incentives for supply chain resilience rather than blanket reshoring commitments. - **FDA compassionate use politicization:** FDA Commissioner McCarry claimed he personally approved 100% of compassionate use requests, a statement HHS later clarified by noting he forwarded requests to appropriate review divisions. Historically, commissioners never handled these approvals — career staff in review divisions do. Sponsors should monitor whether lobbyists now target compassionate use pathways directly, given reports of political pressure influencing review decisions. → NOTABLE MOMENT McCarry's claim of personally signing every compassionate use request alarmed former FDA officials, including ex-Commissioner Robert Califf, who stated commissioners traditionally never handled these approvals. Over 90% of requests are already approved through career staff, making the commissioner's direct involvement structurally unprecedented and a potential signal of broader political interference. 💼 SPONSORS None detected 🏷️ Generics Industry, Biosimilar Regulation, FDA Compassionate Use, US Drug Manufacturing, PBM Reform

AI Summary

→ WHAT IT COVERS Vinay Prasad's departure from CBER leadership creates a second senior FDA vacancy in under a year, while analysis of the Commissioner's National Priority Review Voucher program reveals its fastest approvals rely heavily on the pre-existing Real-Time Oncology Review framework rather than the CNPV mechanism itself. → KEY INSIGHTS - **CBER Leadership Succession:** With Prasad departing in late April 2026, McCary has roughly six weeks to name a replacement — too short for traditional federal hiring. Internal candidates are most likely, including CBER deputy director Catherine Zarema or CDER director Tracy Beth Hogue, who has publicly engaged with vaccine policy despite it falling outside CDER's jurisdiction. - **Vaccine Policy Continuity Risk:** Sponsors expecting Prasad's departure to reset vaccine approval standards should temper expectations. RFK Jr.'s influence over vaccine policy remains intact regardless of who leads CBER, meaning the administration's anti-vaccine posture will likely persist through the upcoming Moderna mRNA flu vaccine decision, which carries a mandatory user fee deadline. - **CNPV Speed Is Borrowed, Not New:** The two fastest CNPV approvals — J&J's Tecvayli/Darzalex Faspro combo at 86 days and Hernexios at 104 days — rank only 13th and 18th on the all-time RTOR speed chart. Both were already in the RTOR pipeline before receiving CNPV designation, meaning the voucher program is accelerating reviews already primed by an older, established mechanism. - **FDA Review Speed Has Declined Since 2021:** Between 2015 and 2021, 14% of all novel FDA approvals had review times of six months or less. Since 2021, no novel agent has been approved in under six months. The CNPV program's speed rhetoric contrasts with this documented slowdown, and industry's actual preference has shifted toward predictability over raw speed. - **RTOR Scalability Limits Apply to CNPV:** RTOR succeeded in oncology because binary life-or-death endpoints made trade-off assessments straightforward and the oncology office operated with relative autonomy. Attempts to replicate this model broadly — including the STAR program, which was dropped in PDUFA negotiations after zero uptake — show that universal fast-track frameworks generate bureaucratic overhead that erodes the speed advantage they promise. → NOTABLE MOMENT McCary publicly framed Prasad's FDA tenure as a planned one-year academic sabbatical from UCSF — a characterization that caught the podcast editors off guard, as no such arrangement had ever been previously disclosed or reported during Prasad's hiring or his earlier reinstatement. 💼 SPONSORS None detected 🏷️ FDA CBER Leadership, Vinay Prasad, Commissioner's National Priority Review Voucher, Real-Time Oncology Review, Vaccine Regulatory Policy

Never miss Drug Fix's insights

Subscribe to get AI-powered summaries of Drug Fix's podcast appearances delivered to your inbox weekly.

Start Free Today

No credit card required • Free tier available